New combo attack targets Cancer's genetic weakness
NCT ID NCT04266912
Summary
This early-phase trial is testing a combination of two drugs, avelumab and M6620, for people with advanced solid tumors that have spread or cannot be removed by surgery. The treatment is specifically for cancers with flaws in certain genes responsible for fixing DNA damage inside cells. The main goals are to find a safe dose and see if this drug combo can help control these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.